Company Analysis

Outlook Therapeutics, Inc. (OTLK)

Nasdaq: OTLK · Biological Products, (No Diagnostic Substances) · Iselin, NJ · filing with the SEC since 2015
Grade3.6
◀ Past 3.5● Present 2.4▶ Future 4.8
4 est.

Who runs Outlook Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Jahr Robert Charles
Chief Executive Officer. First filing Jul 2025, latest Aug 14, 2026, 1 filing in all.
Officers reporting now
3
of 13 people with a filing in the last fifteen months
Directors reporting now
10
32 people on the record since 2016
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Lundquist Kevin MichaelChief Financial OfficerSep 2026Sep 2, 2026none
Jahr Robert CharlesChief Executive OfficerJul 2025Aug 14, 2026none
Kenyon Lawrence AChief Financial OfficerMay 2016Aug 14, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Gms Ventures & InvestmentsdirectorFeb 2020Aug 14, 2026none
Sukhtian Ghiath M.directorSep 2017Aug 14, 2026none
Sukhtian Faisal GhiathdirectorSep 2017Jul 29, 2026none
Haddadin Yezan MuntherdirectorNov 2017Jun 3, 2026none
Hilzinger Kurt JdirectorMay 2016May 27, 2026none
Thurman Randy HdirectorApr 2018May 27, 2026none
Auffarth GerddirectorApr 2020Oct 3, 2025none
Gangolli Julian SdirectorApr 2020Oct 3, 2025none
Haller Julia AdirectorAug 2022Oct 3, 2025none
Huang AndongdirectorJun 2020Oct 3, 2025none
Earlier names on the record20, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton OTLK · research, not advice